$HIND

Vyome Holdings, Inc

0
1
0

No SEC Form 4 filings for $HIND in the last 30 days.

See all $HIND insider activity →
Low

When it comes to rate hikes, CFOs aren't counting on a 'one-and-done'

The Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.

Vyome Holdings, Inc (HIND): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as

Vyome Holdings, Inc (HIND): Results of Operations and Financial Condition

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o

HIND sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning HIND (Vyome Holdings, Inc). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent HIND coverage spans macro economy, corporate actions and earnings.

What's driving HIND

AlphAI scores every news story that mentions HIND with an AI model for sentiment and relevance, and aggregates insider trades from Vyome Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HIND

Score
$HINDLow

When it comes to rate hikes, CFOs aren't counting on a 'one-and-done'

The Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.

$HINDLow

Vyome Holdings, Inc (HIND): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as

$HINDHigh

Vyome Holdings, Inc (HIND): Results of Operations and Financial Condition

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o

Related tickers